CSIMarket
 
Enact Holdings Inc   (NASDAQ: ACT)
Other Ticker:  
 
    Sector  Financial    Industry Insurance Brokerage
   Industry Insurance Brokerage
   Sector  Financial
 
Price: $34.8500 $-0.20 -0.571%
Day's High: $35.38 Week Perf: -1.02 %
Day's Low: $ 34.71 30 Day Perf: -0.54 %
Volume (M): 269 52 Wk High: $ 37.97
Volume (M$): $ 9,386 52 Wk Avg: $34.64
Open: $35.37 52 Wk Low: $30.79



 Market Capitalization (Millions $) 5,329
 Shares Outstanding (Millions) 153
 Employees 465
 Revenues (TTM) (Millions $) 1,217
 Net Income (TTM) (Millions $) 693
 Cash Flow (TTM) (Millions $) 21
 Capital Exp. (TTM) (Millions $) 0

Enact Holdings Inc

Watson Pharmaceuticals, Inc. completed the acquisition of Actavis Group. “Actavis, Inc.” is a leading integrated global specialty pharmaceutical company engaged in the development, manufacturing, marketing, sale and distribution of generic, branded generic, brand, biosimilar and over-the-counter (“OTC”) pharmaceutical products.

Prescription pharmaceutical products in the U.S. generally are marketed as either generic or brand pharmaceuticals. Generic pharmaceutical products are bioequivalents of their respective brand products, or in cases of protein-based biologic therapies, biosimilar, and provide a cost-efficient alternative to brand products. Brand pharmaceutical products are marketed under brand names through programs that are designed to generate physician and consumer loyalty. Through our Anda Distribution Segment, we distribute pharmaceutical products, primarily generics, which have been commercialized by us and others, to pharmacies and physicians’ offices. As a result of the differences between the types of products we market and/or distribute and the methods we distribute these products, we operate and manage our business as three distinct operating segments: Actavis Pharma, Actavis Specialty Brands and Anda Distribution. The Company also develops and out-licenses generic pharmaceutical products through its Medis third-party business.

We apply three key strategies to achieve growth for our Actavis Pharma and Actavis Specialty Brands pharmaceutical businesses: (i) internal development of differentiated and high-demand products, including, in certain circumstances, challenging patents associated with these products, (ii) establishment of strategic alliances and collaborations and (iii) acquisition of products and companies that complement our current business. We believe our three-pronged strategy will allow us to expand both our brand and generic product offerings globally. Our Medis third-party business has a broad portfolio of over 200 developed products for out licensing to approximately 300 customers, primarily in Europe. Our Anda Distribution business distributes products for over 260 suppliers and is focused on providing next-day delivery and responsive service to its customers. Our Anda Distribution business also distributes a number of generic and brand products in the U.S. Growth in our Anda Distribution business will be largely dependent upon FDA approval of new generic products in the U.S. and expansion of our base of suppliers.

Customers
In our Actavis Pharma and Actavis Specialty Brands operations, we sell our generic and brand pharmaceutical products primarily to drug wholesalers, retailers and distributors, including national retail drug and food store chains, hospitals, clinics, mail order, government agencies and managed healthcare providers such as health maintenance organizations and other institutions. In our Anda Distribution business, we distribute generic and certain select brand pharmaceutical products to independent pharmacies, alternate care providers (hospitals, nursing homes and mail order pharmacies), pharmacy chains, physicians’ offices and buying groups.

Competition
The pharmaceutical industry is highly competitive. In our Actavis Pharma and Actavis Specialty Brands businesses, we compete with different companies depending upon product categories, and within each product category, upon dosage strengths and drug delivery systems. Such competitors include the major brand name and generic manufacturers of pharmaceutical products. In addition to product development, other competitive factors in the pharmaceutical industry include product quality and price, reputation and service and access to proprietary and technical information. It is possible that developments by others will make our products or technologies noncompetitive or obsolete.
Competing in the brand product business requires us to identify and bring to market new products embodying technological innovations. Successful marketing of brand products depends primarily on the ability to communicate their effectiveness, safety and value to healthcare professionals in private practice, group practices and receive formulary status from managed care organizations. We anticipate that our brand product offerings will support our existing areas of therapeutic focus. Based upon business conditions and other factors, we regularly reevaluate our business strategies and may from time to time reallocate our resources from one therapeutic area to another, withdraw from a therapeutic area or add an additional therapeutic area in order to maximize our overall growth opportunities. Our competitors in brand products include major brand name manufacturers of pharmaceuticals. Based on total assets, annual revenues and market capitalization, our Actavis Specialty Brands segment is considerably smaller than many of these competitors and other global competitors in the brand product area. Many of our competitors have been in business for a longer period of time, have a greater number of products on the market and have greater financial and other resources than we do. If we directly compete with them for certain contracted business, such as the Pharmacy Benefit Manager business, and for the same markets and/or products, their financial strength could prevent us from capturing a meaningful share of those markets.



   Company Address: 8325 Six Forks Road Raleigh 27615 NC
   Company Phone Number: 846-4100   Stock Exchange / Ticker: NASDAQ ACT


Customers Net Income grew by ACT's Customers Net Profit Margin grew to

53.7 %

4.31 %

• Customers Performance • Customers Expend. • Customers Efficiency • List of Customers


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ABBV   -1.18%    
ABT   -6.33%    
BMY        0.04% 
JNJ        4.39% 
MRK   -4.43%    
PFE   -3.47%    
• View Complete Report
   



Financing Agreement

Navigating the New Landscape: Enact Holdingsn Strategic Moves in Mortgage Insurance and Reinsurance

Published Mon, Jan 27 2025 9:15 PM UTC

In a year marked by economic uncertainties and transformative shifts in the housing finance landscape, Enact Holdings, Inc. (Nasdaq: ACT) emerges as a robust entity dedicated to adapting and thriving. As a leading provider of private mortgage insurance, Enactns recent actions signal not only its resilience but also its commitment to navigating the evolving regulatory framewo...

Product Service News

Enact Holdings, Inc. A Beacon of Prosperity Amidst a Sea of Change in the Mortgage Insurance Realm

Published Wed, Aug 21 2024 10:41 PM UTC

In the fair confines of Raleigh, North Carolina, on this most notable day of August the twenty-first in the year of our Lord two thousand and twenty-four, there emerges a singular announcement from none other than Enact Holdings, Inc. (Nasdaq: ACT). This eminent institution, recognized as a foremost provider of private mortgage insurance via its esteemed subsidiaries, seeks ...

Product Service News

Enact Re, Ltd. Strengthens Market Confidence with Strategic Risk Transfer Moves and Strong S&P Rating

Published Mon, Aug 19 2024 9:06 PM UTC

Enact Re, Ltd., a recognized player in the reinsurance sector, continues to solidify its position and reputation in the global market through strategic initiatives and commendable performance. Recent developments within the company underscore its commitment to robust risk management practices and the effective execution of its diversified credit risk transfer program. Strong...

Dividend

Enact Holdings Inc Reports Second Quarter 2024 Results with $184 Million Net Income and Announces $0.185 Dividend Amidst Significant Stock Surge

Published Wed, Jul 31 2024 8:15 PM UTC

Enact Holdings Inc Reports Impressive Second Quarter 2024 Results: Strong Financial Performance and Stock Surge
Enact Holdings Inc., a leader in the insurance sector, has released its financial results for the second quarter of 2024, showcasing remarkable growth and robust returns that have positively impacted its stock performance. The company announced GAAP net income ...

Contract

Navigating Turbulence Enact Holdings Reinsurance Strategy Amidst Rising Costs and Supplier Challenges

Published Thu, Jun 27 2024 8:10 PM UTC

CSIMarket.com Enact Holdings Inc.: Leveraging Strategic Reinsurance Amidst Supplier Revenue Decline and Surging Sales Costs Enact Holdings Inc., a prominent player in the mortgage insurance industry, has recently made strategic strides by completing an excess of loss (XOL) reinsurance transaction as part of its diversified credit risk transfer program. This significant mo...







Enact Holdings Inc's Segments





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com